Patent SG-11202000325U-A (SG)
Title: Selective inhibitors of nlrp3 inflammasome
Inventor: BOCK MARK G
IPC: C07D241/12
Filed: 2018-07-31
Abstract: 12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau lVIII 0111111v111111010VIIIVIIIioI0III01111111100IIIII100IIIu Hs (43) International Publication Date 07 February 2019 (07.02.2019) (10) International Publication Number WO 2019/025467 Al WIPO I PCT (51) International Patent Classification: C07D 307/87 (2006.01) A61K 31/343 (2006.01) CO7D 231/12 (2006.01) A61K 31/415 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). CO7D 241/12 (2006.01) CO7D 249/08 (2006.01) CO7D 233/56 (2006.01) CO7D 237/08 (2006.01) CO7D 239/26 (2006.01) A61K 31/4164 (2006.01) A61K 31/4965 (2006.01) A61P 29/00 (2006.01) A61P 37/00 (2006.01) (21) International Application Number: PCT/EP2018/070799 (22) International Filing Date: Published: with international search report (Art 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) Filing Language: Publication Language: Priority Data: 1712282.1 31 July 2017 (31.07.2017) GB Applicant: NODTHERA LIMITED [GB/GB]; 20 Char- lotte Square, Edinburgh EH2 4DF (GB). Inventors: BOCK, Mark G.; 285 Columbus Ave., #704, Boston, Massachusetts 02116-5296 (US). WATT, Alan Paul; Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden Essex CB10 1XL (GB). PORTER, Roderick Alan; 89 Back Street, Ashwell, Bal- dock Hertfordshire SG7 5PG (GB). HARRISON, David; Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden Essex CB10 1XL (GB). 31 July 2018 (31.07.2018) English English Agent: COOLEY (UK) LLP; Dashwood, 69 Old Broad Street, London Greater London EC2M 1QS (GB). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (25) (26) (30) (71) (72) (74) (81) (84) N '. (54) Title: SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME O (57) : The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and au- toimmune diseases and cancers. R4